|
|
Post by sportsrancho on Jul 8, 2016 16:38:49 GMT -5
MannKind Corporation to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference VALENCIA, Calif., July 08, 2016 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) (TASE:MNKD) announced today that the Company will present at Cantor Fitzgerald's 2nd Annual Healthcare Conference on Tuesday, July 12, 2016 at 3:30 PM (ET) at the Le Parker Meridien in New York. Presenting from the Company will be its Chief Executive Officer, Matthew J. Pfeffer. Interested parties can access a link to the live webcast of the presentation from the News & Events section of the Company's website at www.mannkindcorp.com. About MannKind Corporation MannKind Corporation (Nasdaq and TASE: MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes. MannKind maintains a website at www.mannkindcorp.com to which MannKind regularly posts copies of its press releases as well as additional information about MannKind. Interested persons can subscribe on the MannKind website to e-mail alerts that are sent automatically when MannKind issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the website. Company Contact: Rose Alinaya SVP, Finance 661-775-5300 ralinaya@mannkindcorp.com You are subscribed to MannKind Corporation Investor Relations' e-mail alerts as sportsrancho@yahoo.com. To update your e-mail and alert preferences, please click here. To unsubscribe, please click here. MannKind Corporation 25134 Rye Canyon Loop Suite 300, Valencia, CA 91355 Service provided by Nasdaq |
|
|
|
Post by mnkdnewb on Jul 8, 2016 17:50:33 GMT -5
IMHO, this may give a bit of guidance on some concerns that we retail investors may have.
|
|
|
|
Post by brentie on Jul 12, 2016 7:48:37 GMT -5
MannKind Corporation to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference VALENCIA, Calif., July 08, 2016 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) (TASE:MNKD) announced today that the Company will present at Cantor Fitzgerald's 2nd Annual Healthcare Conference on Tuesday, July 12, 2016 at 3:30 PM (ET) at the Le Parker Meridien in New York. Presenting from the Company will be its Chief Executive Officer, Matthew J. Pfeffer. Interested parties can access a link to the live webcast of the presentation from the News & Events section of the Company's website at www.mannkindcorp.com. Just a reminder. wsw.com/webcast/cantor4/register.aspx?conf=cantor4&page=mnkd&url=http://wsw.com/webcast/cantor4/mnkd/index.aspx |
|
|
|
Post by liane on Jul 12, 2016 7:57:27 GMT -5
Aw brentie, I liked the previous avatar - you didn't run it long enough! |
|
|
|
Post by brentie on Jul 12, 2016 8:11:44 GMT -5
Aw brentie , I liked the previous avatar - you didn't run it long enough! OK, anything for you, Liane. |
|
|
|
Post by liane on Jul 12, 2016 13:56:02 GMT -5
|
|
|
|
Post by therealisaching on Jul 12, 2016 14:03:39 GMT -5
slides will be up at 3:15
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jul 12, 2016 14:17:24 GMT -5
slides are up and Mike will be presenting
Matt collecting his paycheck?
|
|
|
|
Post by johnhindepost on Jul 12, 2016 14:38:02 GMT -5
Slide 16: MannKind Branded #AFREZZA will launch week of July 25th
|
|
|
|
Post by kc on Jul 12, 2016 14:41:02 GMT -5
Mike is very good..... he is the man. Tells the story very well. love slide 7. Afrezza - Tresiba....
|
|
|
|
Post by gamblerjag on Jul 12, 2016 15:01:41 GMT -5
yes Mike is much better.. He should always speak or speak most of the presentations.. the only downside that I heard was that any international partner will be on hold until they can show scripts increase.. which does make sense.. so guessing no major international partner in the next 6 months. Read more: mnkd.proboards.com/#ixzz4EE6Ow38x |
|
|
|
Post by liane on Jul 12, 2016 15:02:34 GMT -5
hehehe!!!  |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jul 12, 2016 15:10:38 GMT -5
Public speaking is extremely difficult. With that said its better for Mike to speak moving forward. He is excited and you hear it in his voice. Everything they went over is pretty much where I figured we are at. I guess no one was there or did not care as only one question was asked.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jul 12, 2016 15:14:37 GMT -5
yes Mike is much better.. He should always speak or speak most of the presentations.. the only downside that I heard was that any international partner will be on hold until they can show scripts increase.. which does make sense.. so guessing no major international partner in the next 6 months. Read more: mnkd.proboards.com/#ixzz4EE6Ow38xI dont think you can put a time line on it. It all comes down to scripts. They have no negotiating power with the current script numbers. No up front money is coming at current script numbers. No scripts no pass go....You see where I am going with this? |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jul 12, 2016 15:19:39 GMT -5
Mike did a nice job. Lots of infrastructure stuff in July and filling distribution pipeline with Mannkind branded product. Interested to see the new patient help portal that launches in August as this will be if I heard right, a way for patients to handle the prior auth a bit easier. Mike did say NRx should start to grow in August and it sounds like we are for the time being where we are with payors so we get to see how well some of the work arounds do.
Also interesting his comments that basal insulin basically is the key to getting an A1C down in the 8s but below that, it is control of the PPG (post prandial glucose) levels that gets the patient over the goal line. Liane, care to chime in? Me thinks the implication is that a combo therapy is key to A1C< 7.2 and Afrezza is the critical component to drive this and Dexcom will measure and verify. Now if they can set up their own trial with a few hundred patients wear Dex5 sensors that transmit right to the smartphone and send data to Google. Mike could slap the data on the table in front of United and Express Scripts and say, what in your existing therapy regimes can produce a pool of A1C data that shows this much improvement in 6-12 weeks along with endpoint A1C this low. The answer is nothing cause none of the other RAAs can do this. Would be nice if they came up with another $60mm cash. Personally, I don't see what they have lasting until the end of '16. Short Interest jumped a few million per the 6-30 number.
|
|
